Compare Natera Inc. Common Stock (NTRA) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs STMicroelectronics NV — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while STMicroelectronics NV trades at $44.87 (market cap $43.15B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and STMicroelectronics NV pays a 0.77% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and STMicroelectronics NV for 65 Days on average.
| NTRA | STM | |
|---|---|---|
Market Cap | $57.03B | $43.15B |
Volume | 1,131,157 | 14,115,128 |
Sector | Health | Technology |
52-Week High | $425.64 | $79.91 |
52-Week Low | $179.42 | $21.20 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $56.18B | $40.67B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
STM trades at $49.57, down 1.8% on the day, with a bearish technical signal but strong analyst support. The company reported mixed Q2 2026 earnings, beating expectations with $0.31 EPS versus $0.26 expected, while revenue trends show recovery with 26% year-on-year growth in Q2. Valuation metrics appear elevated with a P/E of 94.59, but the company maintains solid cash flow and a strong balance sheet with $6.18 billion in cash.
STM faces near-term profitability challenges with negative net income margins, but strong AI data-center revenue growth projections to exceed $2 billion by 2027 provide upside potential. Key risks include execution on margin improvement and competitive pressures in semiconductor markets. Analyst consensus remains bullish with a $77.31 price target representing 56% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
